Glioma Pipeline Analysis Report 2026

Report Coverage

The Glioma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into glioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for glioma. The glioma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The glioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with glioma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to glioma.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Glioma Pipeline Outlook

Glioma is a group of tumors that develops from glial cells, which support and protect neurons in the central nervous system. It occurs when genetic and molecular changes cause glial cells to grow and divide abnormally, forming tumors in the brain or spinal cord. Gliomas vary by molecular features, grade, location, and aggressiveness.

Treatment includes surgery to remove accessible tumors, followed by radiation therapy and chemotherapy when appropriate. Targeted therapies and clinical trials may be considered based on tumor genetics, grade, recurrence, location, and patient factors. In August 2025, the U.S. Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso) for patients aged 1 year and older with progressive diffuse midline glioma harboring an H3 K27M mutation after prior therapy. The approval marked the first systemic treatment for this population.

Glioma Epidemiology

The pipeline is supported by a significant disease burden and continued clinical research. According to Fassil B. Mesfin et al. (2024), the United States records an estimated 80,000–90,000 new primary brain tumor cases annually, with approximately 25% classified as gliomas. As per M'hamed Bentourkia et al. (2025), glioma incidence in Japan was reported at 6.6 cases per 100,000 persons. These epidemiological trends highlight the need for innovative glioma treatment, targeted therapies, and emerging glioma drugs in clinical development.

Glioma – Pipeline Therapeutic Assessment

Glioma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to Expert Market Research's analysis, phase I and II cover a major share of the total Glioma clinical trials, each accounting for 42% of the drug pipeline. Early phase I represents 8%, and Phase III represents 8%. This strong concentration in early- and mid-stage development supports continued innovation, with a substantial pipeline of investigational therapies expected to advance clinical development and positively expand future treatment opportunities in the market.

Glioma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the glioma pipeline analysis include small molecules, peptides, and oligonucleotides. The glioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for glioma. Alkylating agents in the glioma drug pipeline are being developed to provide new treatment options for malignant gliomas. For instance, tinostamustine is an investigational therapy that combines bifunctional alkylating activity with pan histone deacetylase inhibition. This dual mechanism may enhance tumor cell damage and represents a potential first-in-class approach for treating glioblastoma and other malignant gliomas.

Glioma Clinical Trials – Key Players

The EMR report for the glioma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed glioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in glioma clinical trials:

• HighField Biopharmaceuticals Corporation
• Aveta Biomics, Inc.
• Hutchmed
• Jazz Pharmaceuticals
• Chimerix, Inc.
• Biogenea Pharmaceuticals Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim
• Plus Therapeutics
• ImmVira Pharma Co. Ltd.
• Tcelltech Inc.
• Beijing Bio-Targeting Therapeutics Technology Co., Ltd.

Glioma – Emerging Drugs Profile

Key Questions Answered in the Glioma Pipeline Insight Report

• Which companies/institutions are leading the glioma drug development?
• Which company is leading the glioma pipeline development activities?
• What is the current glioma commercial assessment?
• What are the opportunities and challenges present in the glioma pipeline landscape?
• What is the efficacy and safety profile of glioma pipeline drugs?
• Which company is conducting major trials for glioma drugs?
• Which companies/institutions are involved in glioma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in glioma?

Reasons To Buy This Report

The glioma pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for glioma. It provides necessary information for making informed investment decisions, along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into glioma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Glioma Market

Glioma Epidemiology Forecast